PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Sold by Avior Wealth Management LLC

Avior Wealth Management LLC reduced its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 42.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,062 shares of the company’s stock after selling 1,538 shares during the period. Avior Wealth Management LLC’s holdings in PROCEPT BioRobotics were worth $166,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of PRCT. KRS Capital Management LLC grew its stake in PROCEPT BioRobotics by 0.5% in the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock worth $3,741,000 after purchasing an additional 225 shares in the last quarter. Essex Investment Management Co. LLC grew its position in shares of PROCEPT BioRobotics by 0.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 80,992 shares of the company’s stock worth $6,489,000 after acquiring an additional 228 shares in the last quarter. Values First Advisors Inc. acquired a new position in shares of PROCEPT BioRobotics in the 3rd quarter worth approximately $27,000. KBC Group NV raised its position in shares of PROCEPT BioRobotics by 32.6% during the 3rd quarter. KBC Group NV now owns 1,531 shares of the company’s stock valued at $123,000 after acquiring an additional 376 shares in the last quarter. Finally, Raleigh Capital Management Inc. bought a new position in PROCEPT BioRobotics during the fourth quarter worth $32,000. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Stock Up 1.7 %

PRCT opened at $74.69 on Tuesday. The stock’s 50 day moving average price is $86.14 and its 200 day moving average price is $79.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. The stock has a market cap of $3.90 billion, a P/E ratio of -38.30 and a beta of 1.05. PROCEPT BioRobotics Co. has a 12 month low of $45.20 and a 12 month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Monday, October 28th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. The business had revenue of $58.40 million for the quarter, compared to analysts’ expectations of $53.30 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The company’s revenue was up 66.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.51) earnings per share. As a group, research analysts predict that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current year.

Wall Street Analyst Weigh In

PRCT has been the subject of several recent research reports. Jefferies Financial Group assumed coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a “hold” rating and a $95.00 target price for the company. Truist Financial reiterated a “buy” rating and set a $105.00 price objective (up previously from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. Piper Sandler restated an “overweight” rating and issued a $75.00 target price on shares of PROCEPT BioRobotics in a research note on Tuesday, October 8th. Wells Fargo & Company reiterated an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Finally, Morgan Stanley initiated coverage on PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, PROCEPT BioRobotics currently has a consensus rating of “Moderate Buy” and an average price target of $97.86.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 26,420 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $97.83, for a total value of $2,584,668.60. Following the sale, the chief executive officer now owns 179,185 shares of the company’s stock, valued at approximately $17,529,668.55. The trade was a 12.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Antal Rohit Desai sold 34,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $95.39, for a total value of $3,243,260.00. Following the transaction, the director now directly owns 164,363 shares of the company’s stock, valued at $15,678,586.57. This represents a 17.14 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 462,816 shares of company stock valued at $43,008,799. Company insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).